A $3.5 bln deal with Richard Branson’s blank check company lets the consumer genetic testing firm go public. Robert Cyran explains how the deal gives 23andMe cash, hype and the time it needs for its nascent drug discovery business.
00:46
00:42
01:47
01:01
02:14
00:27
02:51
01:01
01:41
00:59
01:01
01:25
02:04
00:29
02:03
01:12
01:15
02:37
01:30
02:11
02:29
00:57
02:22
00:47
01:22
01:08
01:01
02:59
01:49
00:49
02:23
00:50
02:26
01:53
00:45
01:09
00:55
01:27
00:49
00:45
01:01
00:27
01:15
01:30
02:37
00:40
00:40
00:30
01:15
00:17
02:26
00:47
00:28
00:52
00:33
01:05
00:25
01:59
01:34
00:33
01:02
01:28
01:57
01:03
02:00
03:34
01:30
00:51
02:02
00:51
02:07
02:05
01:36
01:23
02:26
01:11
00:28
01:38
01:00
01:23
02:14
01:18
01:09
01:23
01:26
01:35
01:07
02:52
05:07
01:11
01:01
01:42
01:55
01:29
00:59
00:49
00:57
01:41
02:09
01:36